Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons

키워드

참고문헌 (133)

1. Robert E Marx, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", Journal of Oral and Maxillofacial Surgery, 61(9), pp.1115~1117 (2003), Elsevier BV[DOI]
2. Salvatore L. Ruggiero, "American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update", Journal of Oral and Maxillofacial Surgery, 72(10), pp.1938~1956 (2014), Elsevier BV[DOI]
3. 김경민, "Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons", 대한골대사학회지, 22(4), pp.151~165 (2015), 대한골대사학회
4. 이정근, "Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report", 대한구강악안면외과학회지, 39(1), pp.9~13 (2013), 대한구강악안면외과학회
5. Se Hwa Kim, "Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study", Bone, 143, pp.115650~ (2021), Elsevier BV[DOI]
6. ALIYA A. KHAN, "Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons", The Journal of Rheumatology, 38(7), pp.1396~1402 (2011), The Journal of Rheumatology[DOI]
7. Mattias Ulmner, "Osteonecrosis of the Jaw in Sweden Associated With the Oral Use of Bisphosphonate", Journal of Oral and Maxillofacial Surgery, 72(1), pp.76~82 (2014), Elsevier BV[DOI]
8. Etminan M, "Use of oral bisphosphonates and the risk of aseptic osteonecrosis : a nested case-control study", J Rheumatol, 35, pp.691~695 (2008)
9. Kenneth W. Lyles, "Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture", New England Journal of Medicine, 357(18), pp.1799~1809 (2007), Massachusetts Medical Society[DOI]
10. Patricia Sieber, "Intravenous Bisphosphonates for Postmenopausal Osteoporosis: Safety Profiles of Zoledronic Acid and Ibandronate in Clinical Practice", Clinical Drug Investigation, 33(2), pp.117~122 (2013), Springer Science and Business Media LLC[DOI]
11. Patricia Tennis, "Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis", Pharmacoepidemiology and Drug Safety, 21(8), pp.810~817 (2012), Wiley[DOI]
12. Nick Malden, "An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence", Journal of Bone and Mineral Metabolism, 30(2), pp.171~182 (2012), Springer Science and Business Media LLC[DOI]
13. F. Saad, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases", Annals of Oncology, 23(5), pp.1341~1347 (2012), Elsevier BV[DOI]
14. Aliya A Khan, "Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus", Journal of Bone and Mineral Research, 30(1), pp.3~23 (2015), Wiley[DOI]
15. T. Sugimoto, "Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)", Osteoporosis International, 26(2), pp.765~774 (2015), Springer Science and Business Media LLC[DOI]
16. Dino Amadori, "Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial", The Lancet Oncology, 14(7), pp.663~670 (2013), Elsevier BV[DOI]
17. Aristotle Bamias, "Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors", Journal of Clinical Oncology, 23(34), pp.8580~8587 (2005), American Society of Clinical Oncology (ASCO)[DOI]
18. J. W. Hong, "Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia", Osteoporosis International, 21(5), pp.847~853 (2010), Springer Science and Business Media LLC[DOI]
19. Ana O Hoff, "Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates", Journal of Bone and Mineral Research, 23(6), pp.826~836 (2008), Wiley[DOI]
20. F. Jadu, "A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients", Annals of Oncology, 18(12), pp.2015~2019 (2007), Elsevier BV[DOI]
21. Masahiro Urade, "Nationwide Survey for Bisphosphonate-Related Osteonecrosis of the Jaws in Japan", Journal of Oral and Maxillofacial Surgery, 69(11), pp.e364~e371 (2011), Elsevier BV[DOI]
22. Vassiliki M. Cartsos, "Bisphosphonate Use and the Risk of Adverse Jaw Outcomes", The Journal of the American Dental Association, 139(1), pp.23~30 (2008), Elsevier BV[DOI]
23. J.L. Fellows, "ONJ in Two Dental Practice-Based Research Network Regions", Journal of Dental Research, 90(4), pp.433~438 (2011), SAGE Publications[DOI]
24. D. Powell, "Incidence of serious side effects with intravenous bisphosphonate: a clinical audit", QJM, 105(10), pp.965~971 (2012), Oxford University Press (OUP)[DOI]
25. Joan C. Lo, "Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure", Journal of Oral and Maxillofacial Surgery, 68(2), pp.243~253 (2010), Elsevier BV[DOI]
26. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, "American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws", Journal of Oral and Maxillofacial Surgery, 65(3), pp.369~376 (2007), Elsevier BV[DOI]
27. Toshiyuki Yoneda, "Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons", Journal of Bone and Mineral Metabolism, 28(4), pp.365~383 (2010), Springer Science and Business Media LLC[DOI]
28. G. Subramanian, "Osteonecrosis and atypical fractures—common origins?", Osteoporosis International, 24(2), pp.745~746 (2013), Springer Science and Business Media LLC[DOI]
29. Regina Landesberg, "Potential pathophysiological mechanisms in osteonecrosis of the jaw", Annals of the New York Academy of Sciences, 1218(1), pp.62~79 (2011), Wiley[DOI]
30. Sebastian Hoefert, "Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings", Clinical Oral Investigations, 14(3), pp.271~284 (2010), Springer Science and Business Media LLC[DOI]
31. R. G. G. Russell, "Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy", Osteoporosis International, 19(6), pp.733~759 (2008), Springer Science and Business Media LLC[DOI]
32. Matthew R. Allen, "Bisphosphonates and Osteonecrosis of the Jaw: Moving from the Bedside to the Bench", Cells Tissues Organs, 189(1-4), pp.289~294 (2009), S. Karger AG[DOI]
33. Matthew R. Allen, "The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing", Odontology, 99(1), pp.8~17 (2011), Springer Science and Business Media LLC[DOI]
34. Matthew R Allen, "Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs", Journal of Bone and Mineral Research, 25(1), pp.98~105 (2010), Wiley[DOI]
35. Philippe Lesclous, "Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?", Bone, 45(5), pp.843~852 (2009), Elsevier BV[DOI]
36. Felice S. O'Ryan, "Intravenous Bisphosphonate-Related Osteonecrosis of the Jaw: Bone Scintigraphy as an Early Indicator", Journal of Oral and Maxillofacial Surgery, 67(7), pp.1363~1372 (2009), Elsevier BV[DOI]
37. Parish P. Sedghizadeh, "Microbial Biofilms in Osteomyelitis of the Jaw and Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy", The Journal of the American Dental Association, 140(10), pp.1259~1265 (2009), Elsevier BV[DOI]
38. Per Aspenberg, "Osteonecrosis of the jaw: what do bisphosphonates do?", Expert Opinion on Drug Safety, 5(6), pp.743~745 (2006), Informa Healthcare[DOI]
39. Per Aspenberg, "Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures", Journal of Bone and Mineral Research, 25(2), pp.404~414 (2010), Wiley[DOI]
40. Santini D, "Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients", Clin Cancer Res, 9, pp.2893~2897 (2003)
41. Matthew R. Allen, "The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data", Journal of Oral and Maxillofacial Surgery, 67(5), pp.61~70 (2009), Elsevier BV[DOI]
42. Junro Yamashita, "Effect of Zoledronate on Oral Wound Healing in Rats", Clinical Cancer Research, 17(6), pp.1405~1414 (2011), American Association for Cancer Research (AACR)[DOI]
43. Sebastian Hoefert, "Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 110(4), pp.463~469 (2010), Elsevier BV[DOI]
44. Wynn RL, "Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw", Gen Dent, 59, pp.410~413 (2011)
45. Junro Yamashita, "Antiresorptives and Osteonecrosis of the Jaw", Journal of Evidence Based Dental Practice, 12(3), pp.233~247 (2012), Elsevier BV[DOI]
46. Ian R. Reid, "Osteonecrosis of the jaw — Who gets it, and why?", Bone, 44(1), pp.4~10 (2009), Elsevier BV[DOI]
47. Ian R. Reid, "Epidemiology and pathogenesis of osteonecrosis of the jaw", Nature Reviews Rheumatology, 8(2), pp.90~96 (2012), Springer Science and Business Media LLC[DOI]
48. Takefumi Oizumi, "Inhibition of Necrotic Actions of Nitrogen-Containing Bisphosphonates (NBPs) and Their Elimination From Bone by Etidronate (a Non-NBP): A Proposal for Possible Utilization of Etidronate as a Substitution Drug for NBPs", Journal of Oral and Maxillofacial Surgery, 68(5), pp.1043~1054 (2010), Elsevier BV[DOI]
49. Addolorata Corrado, "Extra-skeletal effects of bisphosphonates", Joint Bone Spine, 74(1), pp.32~38 (2007), Elsevier BV[DOI]
50. Vivek Thumbigere-Math, "A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates", American Journal of Clinical Oncology, 35(4), pp.386~392 (2012), Ovid Technologies (Wolters Kluwer Health)[DOI]
51. Matthew R. Allen, "Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate", Bone, 39(4), pp.872~879 (2006), Elsevier BV[DOI]
52. J. Compston, "Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw", Osteoporosis International, 22(12), pp.2951~2961 (2011), Springer Science and Business Media LLC[DOI]
53. Jin-Woo Kim, "Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw", Clinical Oral Investigations, 20(8), pp.2251~2258 (2016), Springer Science and Business Media LLC[DOI]
54. Y.-D. Kwon, "Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws", Osteoporosis International, 23(11), pp.2721~2725 (2012), Springer Science and Business Media LLC[DOI]
55. W. Park, "Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases", Osteoporosis International, 21(3), pp.527~533 (2010), Springer Science and Business Media LLC[DOI]
56. Steven R. Cummings, "Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis", New England Journal of Medicine, 361(8), pp.756~765 (2009), Massachusetts Medical Society[DOI]
57. Henry G Bone, "10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension", The Lancet Diabetes & Endocrinology, 5(7), pp.513~523 (2017), Elsevier BV[DOI]
58. Ayaka Inada, "Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database", Therapeutics and Clinical Risk Management, 15, pp.59~64 (2019), Informa UK Limited[DOI]
59. T. Yamazaki, "Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study", International Journal of Oral and Maxillofacial Surgery, 41(11), pp.1397~1403 (2012), Elsevier BV[DOI]
60. K McGowan, "Risk factors for medication-related osteonecrosis of the jaws: A systematic review", Oral Diseases, 24(4), pp.527~536 (2018), Wiley[DOI]
61. Toshiyuki Yoneda, "Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw", Journal of Bone and Mineral Metabolism, 35(1), pp.6~19 (2017), Springer Science and Business Media LLC[DOI]
62. Maria Luisa Brandi, "Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw", Frontiers in Bioscience, 3(1), pp.364~370 (2011), IMR Press[DOI]
63. English BC, "A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer", Therapeutics and Clinical Risk Management, 6, pp.579~583 (2010), Informa UK Limited[DOI]
64. Jin-Woo Kim, "Machine Learning Approaches for Predicting Bisphosphonate-Related Osteonecrosis in Women with Osteoporosis Using VEGFA Gene Polymorphisms", Journal of Personalized Medicine, 11(6), pp.541~ (2021), MDPI AG[DOI]
65. Guang Yang, "SIRT1", HERC4 locus associated with bisphosphonate-induced osteonecrosis of the jaw: an exome-wide association analysis, 2018, pp.33(1), 91~98[DOI]
66. Nobuhiro Ueda, "Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer", Journal of Bone and Mineral Metabolism, 39(4), pp.623~630 (2021), Springer Science and Business Media LLC[DOI]
67. Giuseppina Campisi, "Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian Consensus Update 2020", International Journal of Environmental Research and Public Health, 17(16), pp.5998~ (2020), MDPI AG[DOI]
68. Nobuhiro Ueda, "Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?", Clinical Oral Investigations, 25(5), pp.3087~3093 (2021), Springer Science and Business Media LLC[DOI]
69. 최우성, "Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma", Maxillofacial Plastic Reconstructive Surgery, 39(1), pp.1~7 (2017), 대한악안면성형재건외과학회[DOI]
70. Kunimichi Niibe, "Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab", Journal of Prosthodontic Research, 59(1), pp.3~5 (2015), Japan Prosthodontic Society[DOI]
71. Ourania Nicolatou‐Galitis, "Alveolar bone histological necrosis observed prior to extractions in patients, who received bone‐targeting agents", Oral Diseases, 26(5), pp.955~966 (2020), Wiley[DOI]
72. Torben Smidt-Hansen, "Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma", Journal of Oral and Maxillofacial Surgery, 71(9), pp.1532~1540 (2013), Elsevier BV[DOI]
73. Matthew S. Epstein, "The effects of osteoclast modifiers on the oral cavity", Current Opinion in Supportive & Palliative Care, 6(3), pp.337~341 (2012), Ovid Technologies (Wolters Kluwer Health)[DOI]
74. John W. Hellstein, "Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs", The Journal of the American Dental Association, 142(11), pp.1243~1251 (2011), Elsevier BV[DOI]
75. M.A. Dimopoulos, "Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid", Annals of Oncology, 20(1), pp.117~120 (2009), Elsevier BV[DOI]
76. C.I. Ripamonti, "Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan", Annals of Oncology, 20(1), pp.137~145 (2009), Elsevier BV[DOI]
77. Bonacina R, "Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw : a review of 282 patients", J Can Dent Assoc, 77, pp.b147~ (2011)
78. Harry Karna, "Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses", Oral Oncology, 85, pp.15~23 (2018), Elsevier BV[DOI]
79. Damm DD, "Bisphosphonate-related osteonecrosis of the jaws : a potential alternative to drug holidays", Gen Dent, 61, pp.33~38 (2013)
80. K.H. Taylor, "Osteonecrosis of the jaws induced by anti-RANK ligand therapy", British Journal of Oral and Maxillofacial Surgery, 48(3), pp.221~223 (2010), Elsevier BV[DOI]
81. Tara L. Aghaloo, "Osteonecrosis of the Jaw in a Patient on Denosumab", Journal of Oral and Maxillofacial Surgery, 68(5), pp.959~963 (2010), Elsevier BV[DOI]
82. Alison T. Stopeck, "Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer", Supportive Care in Cancer, 24(1), pp.447~455 (2016), Springer Science and Business Media LLC[DOI]
83. Akanksha Srivastava, "Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis", Supportive Care in Cancer, 29(5), pp.2305~2317 (2021), Springer Science and Business Media LLC[DOI]
84. Henry G. Bone, "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass", The Journal of Clinical Endocrinology & Metabolism, 96(4), pp.972~980 (2011), The Endocrine Society[DOI]
85. Steven R Cummings, "Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension", Journal of Bone and Mineral Research, 33(2), pp.190~198 (2018), Wiley[DOI]
86. Robert E. Marx, "Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment", Journal of Oral and Maxillofacial Surgery, 65(12), pp.2397~2410 (2007), Elsevier BV[DOI]
87. Mohamed E. Awad, "Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis", The Journal of the American Dental Association, 150(8), pp.664~675.e8 (2019), Elsevier BV[DOI]
88. Jin-Woo Kim, "Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates", Bone, 57(1), pp.201~205 (2013), Elsevier BV[DOI]
89. Jose V. Bagan, "Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates", Oral Oncology, 44(11), pp.1088~1089 (2008), Elsevier BV[DOI]
90. Yong-Dae Kwon, "Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?", Clinical Oral Implants Research, 22(1), pp.100~105 (2011), Wiley[DOI]
91. Yong-Dae Kwon, "Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws", Journal of Oral and Maxillofacial Surgery, 67(12), pp.2644~2648 (2009), Elsevier BV[DOI]
92. Jin-Woo Kim, "Biomarkers for Bisphosphonate-Related Osteonecrosis of the Jaw", Clinical Implant Dentistry and Related Research, 18(2), pp.281~291 (2016), Wiley[DOI]
93. Jung-Hyun Park, "Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study", Osteoporosis International, 33(2), pp.367~377 (2022), Springer Science and Business Media LLC[DOI]
94. Andreas Stavropoulos, "The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis", Clinical Oral Implants Research, 29(Suppl 18), pp.54~92 (2018), Wiley[DOI]
95. Jae‐In Ryu, "Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study", Clinical Oral Implants Research, 32(4), pp.437~447 (2021), Wiley[DOI]
96. Tae-Geon Kwon, "Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment", Clinical Oral Implants Research, 25(5), pp.632~640 (2014), Wiley[DOI]
97. Christine Jacobsen, "Osteopathology induced by bisphosphonates and dental implants: clinical observations", Clinical Oral Investigations, 17(1), pp.167~175 (2013), Springer Science and Business Media LLC[DOI]
98. Towy Sorel Lazarovici, "Bisphosphonate-Related Osteonecrosis of the Jaw Associated With Dental Implants", Journal of Oral and Maxillofacial Surgery, 68(4), pp.790~796 (2010), Elsevier BV[DOI]
99. 김윤호, "Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw", 대한구강악안면외과학회지, 40(5), pp.206~210 (2014), 대한구강악안면외과학회
100. Nicole V. Hinchy, "Osteonecrosis of the jaw – Prevention and treatment strategies for oral health professionals", Oral Oncology, 49(9), pp.878~886 (2013), Elsevier BV[DOI]
101. Valentina Guarneri, "Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer", Breast Cancer Research and Treatment, 122(1), pp.181~188 (2010), Springer Science and Business Media LLC[DOI]
102. Claudine Tsao, "Oral Health Risk Factors for Bisphosphonate-Associated Jaw Osteonecrosis", Journal of Oral and Maxillofacial Surgery, 71(8), pp.1360~1366 (2013), Elsevier BV[DOI]
103. Monique Chalem, "Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts", Archives of Osteoporosis, 15(1), pp.101~ (2020), Springer Science and Business Media LLC[DOI]
104. Cesar A. Migliorati, "Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction", The Journal of the American Dental Association, 144(4), pp.406~414 (2013), Elsevier BV[DOI]
105. Kenneth E. Fleisher, "Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 110(4), pp.509~516 (2010), Elsevier BV[DOI]
106. Akira Taguchi, "Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group", Calcified Tissue International, 97(6), pp.542~550 (2015), Springer Science and Business Media LLC[DOI]
107. Eric R. Carlson, "The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the Jaws", Journal of Oral and Maxillofacial Surgery, 67(5), pp.85~95 (2009), Elsevier BV[DOI]
108. Sebastiano Ferlito, "Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases", British Journal of Oral and Maxillofacial Surgery, 50(5), pp.425~429 (2012), Elsevier BV[DOI]
109. Matteo Scoletta, "Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 110(1), pp.46~53 (2010), Elsevier BV[DOI]
110. Deepak Kademani, "Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy", Mayo Clinic Proceedings, 81(8), pp.1100~1103 (2006), Elsevier BV[DOI]
111. John J. Freiberger, "What Is the Role of Hyperbaric Oxygen in the Management of Bisphosphonate-Related Osteonecrosis of the Jaw: A Randomized Controlled Trial of Hyperbaric Oxygen as an Adjunct to Surgery and Antibiotics", Journal of Oral and Maxillofacial Surgery, 70(7), pp.1573~1583 (2012), Elsevier BV[DOI]
112. Jung-Hyun Park, "Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?", Journal of Oral and Maxillofacial Surgery, 75(6), pp.1176~1184 (2017), Elsevier BV[DOI]
113. Jin-Woo Kim, "Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study", British Journal of Oral and Maxillofacial Surgery, 52(9), pp.854~859 (2014), Elsevier BV[DOI]
114. Paolo Vescovi, "Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients", Journal of Oral Pathology & Medicine, 41(3), pp.214~221 (2012), Wiley[DOI]
115. Song KE, "A probable case of oral bisphosphonate-associated osteonecrosis of the jaw and recovery with parathyroid hormone treatment", Curr Ther Res Clin Exp, 69, pp.356~362 (2008)[DOI]
116. Jill D. Bashutski, "Teriparatide and Osseous Regeneration in the Oral Cavity", New England Journal of Medicine, 363(25), pp.2396~2405 (2010), Massachusetts Medical Society[DOI]
117. David A. Gerard, "Early Inhibitory Effects of Zoledronic Acid in Tooth Extraction Sockets in Dogs Are Negated by Recombinant Human Bone Morphogenetic Protein", Journal of Oral and Maxillofacial Surgery, 72(1), pp.61~66 (2014), Elsevier BV[DOI]
118. 2.0.Co;2,
119. Stefano Fedele, "Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series", The American Journal of Medicine, 123(11), pp.1060~1064 (2010), Elsevier BV[DOI]
120. Morten Schiodt, "Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 117(2), pp.204~213 (2014), Elsevier BV[DOI]
121. Noam Yarom, "Medication-Related Osteonecrosis of the Jaw: MASCC", ISOO, Journal of Clinical Oncology, pp.2019, 37(25)[DOI]
122. Andrew M. Hinson, "Temporal Correlation Between Bisphosphonate Termination and Symptom Resolution in Osteonecrosis of the Jaw: A Pooled Case Report Analysis", Journal of Oral and Maxillofacial Surgery, 73(1), pp.53~62 (2015), Elsevier BV[DOI]
123. Stephanie K A Blick, "Teriparatide: a review of its use in osteoporosis", Drugs, 68(18), pp.2709~2737 (2008), Springer Science and Business Media LLC[DOI]
124. Mishaela R Rubin, "The anabolic effects of parathyroid hormone therapy", Clinics in Geriatric Medicine, 19(2), pp.415~432 (2003), Elsevier BV[DOI]
125. Michael R. McClung, "Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass", Archives of Internal Medicine, 165(15), pp.1762~1768 (2005), American Medical Association (AMA)[DOI]
126. Ada Cheung, "Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw", New England Journal of Medicine, 363(25), pp.2473~2474 (2010), Massachusetts Medical Society[DOI]
127. Jang-Jaer Lee, "Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy", Head & Neck, 33(9), pp.1366~1371 (2011), Wiley[DOI]
128. K. M. Kim, "Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw", Osteoporosis International, 25(5), pp.1625~1632 (2014), Springer Science and Business Media LLC[DOI]
129. Junho Jung, "Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study", Journal of Bone and Mineral Research, 32(12), pp.2445~2452 (2017), Wiley[DOI]
130. Ie-Wen Sim, "Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial", Journal of Clinical Oncology, 38(26), pp.2971~2980 (2020), American Society of Clinical Oncology (ASCO)[DOI]
131. Robinder S Dhillon, "PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis", Journal of Bone and Mineral Research, 28(3), pp.586~597 (2013), Wiley[DOI]
132. A. Gilsenan, "Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study", Osteoporosis International, 32(4), pp.645~651 (2021), Springer Science and Business Media LLC[DOI]
133. Alicia Gilsenan, "Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study", Journal of Bone and Mineral Research, 36(2), pp.244~251 (2021), Wiley[DOI]

관련 논문AI추천